Daniela Proske1, Michael Blank, Raymund Buhmann
1NascaCell IP GmbH, 3. OG, Modul D Max-Lebsche-Platz, 3181377 Munich, Germany. d.proske@nascacell.de
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Aptamer technology, using DNA and RNA sequences, has advanced significantly for targeting proteins. These aptamers show great promise in biotechnology, diagnostics, and therapeutics.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: